RhumbLine Advisers’s Sana Biotechnology SANA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $555K | Buy |
203,283
+21,149
| +12% | +$57.7K | ﹤0.01% | 2624 |
|
|
2025
Q1 | $306K | Buy |
182,134
+9,359
| +5% | +$15.7K | ﹤0.01% | 2877 |
|
|
2024
Q4 | $282K | Buy |
172,775
+987
| +0.6% | +$1.61K | ﹤0.01% | 3027 |
|
|
2024
Q3 | $715K | Sell |
171,788
-10,115
| -6% | -$42.1K | ﹤0.01% | 2465 |
|
|
2024
Q2 | $993K | Buy |
181,903
+25,056
| +16% | +$137K | ﹤0.01% | 2253 |
|
|
2024
Q1 | $1.57M | Buy |
156,847
+4,863
| +3% | +$48.6K | ﹤0.01% | 2028 |
|
|
2023
Q4 | $620K | Buy |
151,984
+1,866
| +1% | +$7.61K | ﹤0.01% | 2542 |
|
|
2023
Q3 | $581K | Sell |
150,118
-2,732
| -2% | -$10.6K | ﹤0.01% | 2522 |
|
|
2023
Q2 | $911K | Buy |
152,850
+10,258
| +7% | +$61.1K | ﹤0.01% | 2345 |
|
|
2023
Q1 | $466K | Buy |
142,592
+4,260
| +3% | +$13.9K | ﹤0.01% | 2471 |
|
|
2022
Q4 | $546K | Buy |
138,332
+770
| +0.6% | +$3.04K | ﹤0.01% | 2423 |
|
|
2022
Q3 | $825K | Buy |
137,562
+7,543
| +6% | +$45.2K | ﹤0.01% | 2247 |
|
|
2022
Q2 | $836K | Buy |
130,019
+39,323
| +43% | +$253K | ﹤0.01% | 2223 |
|
|
2022
Q1 | $749K | Buy |
90,696
+5,518
| +6% | +$45.6K | ﹤0.01% | 2251 |
|
|
2021
Q4 | $1.32M | Buy |
85,178
+1,529
| +2% | +$23.7K | ﹤0.01% | 2092 |
|
|
2021
Q3 | $1.88M | Buy |
83,649
+59,808
| +251% | +$1.35M | ﹤0.01% | 1939 |
|
|
2021
Q2 | $469K | Buy |
23,841
+2,860
| +14% | +$56.3K | ﹤0.01% | 2592 |
|
|
2021
Q1 | $702K | Buy |
+20,981
| New | +$702K | ﹤0.01% | 2344 |
|